库拉肿瘤

Kura Oncology Inc earns a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 32% discount to our quantitative fair value estimate of $15.69 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to market value ratio of 0.5, which falls in the bottom 10% compared with global peers. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. We believe this is a sign that shares could be cheap.

The firm's balance sheet is an additional encouraging factor. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 4.7, a core component of leverage, sits in the top 20% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.